Kaitlyn D’Onofrio

DocwireNews

A randomized trial found no benefit of adjuvant denosumab in <a href="https://www.docwirenews.com/conference-coverage/san-antonio_breast_cancer_symposiom_2019/what-do-patients-doctors-nurses-consider-most-important-breast-cancer-education/">early breast cancer</a>.&ldquo;Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would increase bone metastasis-free survival in women with breast cancer,&rdquo; the researchers wrote in their introduction.D-CARE was an international, double-blind, randomized, placebo-controlled, phase 3 study including patients from 389 institutions spanning 39 countries. Women aged 18 years or older with confirmed stage II or III breast cancer who had an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion. Patients were randomized 1:1 to receive either denosumab 120 mg or placebo every three to four weeks, beginning with neoadjuvant or adjuvant chemotherapy, for six months, followed by every 12 weeks for five years in total. The main outcome measure was bone metastasis-free survival.Randomization of 4,509 patients took place from June 2, 2010 through Aug. 24, 2012; 2,256 women were placed in the denosumab group and 2,253 in the placebo group. Bone metastasis-free survival did not largely differ between the groups (median not reached in either group; hazard ratio=0.97; 95% CI, 0.82-1.14; P=0.70). Treatment-emergent adverse events grade 3 or worse were reported in 2,241 denosumab patients and 2,218 placebo patients, the most common of which were neutropenia (340 [15%] vs. 328 [15%]), febrile neutropenia (112 [5%] vs. 142 [6%]), and leucopenia (62 [3%] vs. 61 [3%]). Denosumab patients were more likely to develop positively adjudicated osteonecrosis of the jaw (n = 122 [5%]) compared to placebo patients (n = 4 [&lt;1%]), as well as treatment-emergent hypocalcemia (n = 152 [7%] vs. n = 82 [4%]). Two placebo patients died, due to acute myeloid leukemia and depressed level of consciousness.The results of the study were published in <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30687-4/fulltext">The Lancet Oncology</a>.The study authors concluded, &ldquo;Despite preclinical evidence suggesting RANKL inhibition might delay bone metastasis or disease recurrence in patients with early-stage breast cancer, in this study, denosumab did not improve disease-related outcomes for women with high-risk early breast cancer.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Denosumab Flops in Breast Cancer Study

Breast Cancer News

A randomized trial found no benefit of adjuvant denosumab in early breast cancer. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe